Das smart lab Carinthia bietet Ihnen eine individuelle Auswahl an Kurse, Workshops & Seminaren fr Ihre Organisation und Bildungseinrichtung an. Announce Stockholder Approval of t.. Ladenburg Thalmann Starts Healthcare Capital at Buy With $18 Price Target. Alpha Tau may not realize its expectations, and its beliefs may not prove correct. Healthcare Capital Corp (NASDAQ: HCCC, HCCCW, and HCCCU) is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. Announce Completion of Business Combination by PRNewswire March 7, 2022 8:32 AM | 6 min read JERUSALEM and WILMINGTON, Del., March 7, 2022. Additional information regarding the interests of those persons and other persons who may be deemed participants in the proposed transaction may be obtained by reading the proxy statement/prospectus regarding the proposed transaction. While Alpha Tau may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. "As we redouble our efforts to bring our Alpha DaRT technology to patients around the world, we are confident that this significant inflow of funds will carry us through a significant number of meaningful milestones. NEW YORK, New York and JERUSALEM, Israel, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Healthcare Capital Corp (NASDAQ: HCCC, HCCCW, and HCCCU) ("HCCC") today announced that on January 12, 2022, the. , , , , , , Environmental, Social and Governance (ESG), HVAC (Heating, Ventilation and Air-Conditioning), Machine Tools, Metalworking and Metallurgy, Aboriginal, First Nations & Native American, https://mma.prnewswire.com/media/733268/Alpha_Tau_Medical_Logo.jpg. Alpha Tau Medical and Healthcare Capital Corp. Type a symbol or company name. This announcement is for informational purposes only and is neither an offer to purchase, nor a solicitation of an offer to sell, subscribe for or buy any securities or the solicitation of any vote in any jurisdiction pursuant to the proposed Business Combination or otherwise, nor shall there be any sale, issuance or transfer or securities in any jurisdiction in contravention of applicable law. - All Alpha Tau shareholders will retain 100% of their equity holdings in the public company. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. Cision Distribution 888-776-0942 Value Base M&A Ltd. acted as financial advisor to HCCC. New Velden am Wrther See, Carinthia, Austria jobs added daily. Potential candidates will appreciate our experienced operator mindset, industry, and global connections that can facilitate strategic partnerships and expansion opportunities as well as ease their transition to public ownership. Use tab to navigate through the menu items. Value Base M&A Ltd. acted as financial advisor to HCCC. Any such forward-looking statements represent managements estimates as of the date of this press release. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it. While HCCC and Alpha Tau may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. Before making any voting or investment decision, investors and security holders are urged to read the registration statement, the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transaction as they become available because they will contain important information about the proposed transaction. All forward-looking statements are based upon Alpha Tau's and HCCC's current expectations and various assumptions. These forward-looking statements should not be relied upon as representing Alpha Tau's views as of any date subsequent to the date of this press release. Through completion of the Business Combination, Alpha Tau has raised approximately $90 million in gross cash proceeds. All forward-looking statements are based upon Alpha Tau's and HCCC's current expectations and various assumptions. Any such forward-looking statements represent management's estimates as of the date of this press release. Winston & Strawn LLP acted as legal advisor to the placement agents. A Current Report on Form 8-K disclosing the full voting results was filed by HCCC with the Securities and Exchange Commission on February 22, 2022. Copyright 2023 Surperformance. Proceeds of the business combination and the PIPE will be primarily used to: The Business Combination values Alpha Tau at an implied pre-money equity value of $600 million, and is expected to add approximately $337 million of cash to its balance sheet upon closing, inclusive of $275 million in HCC's trust (assuming no redemptionsby public shareholders) and $92 million in PIPE proceeds, net of transaction expenses. The Special Meeting will be held as a virtual meeting via live audio webcast at https://www.cstproxy.com/healthcarecapitalcorp/2022. When used herein, words including "anticipate," "being," "will," "plan," "may," "continue," and similar expressions are intended to identify forward-looking statements. "We look forward to delivering continued clinical momentumand hope for patients as we evolve into a public company. Announce Completion of Business Combination - Form 8-K. Healthcare Capital Corp/de : Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Righ.. https://mma.prnewswire.com/media/733268/Alpha_Tau_Medical_Logo.jpg, https://www.prnewswire.com/news-releases/alpha-tau-announces-new-research-collaboration-to-study-the-potential-of-alpha-dart-to-enhance-immune-stimulation-in-the-treatment-of-breast-cancer-301464365.html. Alpha Tau Announces Results of First US Clinical Trial of Alpha DaRT in Malignant Skin & Soft Tissue Cancers, Showing Complete Response in All Ten Treated Tumors at Approximately 12 Weeks and No Product-Related Serious Adverse Events Alpha Tau Announces Completion of Enrollment of Japanese Pivotal Clinical Trial in Recurrent Head & Neck Cancer This will afford us the ability to drive the company forward as we continue to execute on our ambitious plans around the world.". ", "It was a pleasure to work with the team at HCC as their due diligence advisor following my departure as Commissioner of the FDA in January 2021," said Dr. Stephen M. Hahn. Alpha Tau Medical and Healthcare Capital Corp. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. Piper Sandler and Cantor Fitzgerald acted as joint placement agents on the PIPE. Delayed Nasdaq No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. Stockholders may also obtain copies of the Registration Statement, proxy statement/prospectus, and Form 8-K, without charge at the SEC's website at www.sec.gov. Alpha Tau may not realize its expectations, and its beliefs may not prove correct. All forward-looking statements are based upon Alpha Taus and HCCCs current expectations and various assumptions. Contact: Amnon Gat+972-54-9746276amnong@alphatau.com, Logo - https://mma.prnewswire.com/media/733268/Alpha_Tau_Medical_Logo.jpg. Citigroup acted as lead financial advisor to Alpha Tau. combination (the "Business Combination") between Healthcare Capital Corp. ("HCCC") and Alpha Tau Medical Ltd. ("Alpha Tau" orthe "Company"). I would expect the product to be well received by the clinical community because of the potential applications, modest side effect profile, and demonstrated potency of the Alpha DaRTTM". from 8 AM - 9 PM ET. As such, the DaRT platform leverages the benefits ofbrachytherapy as well as the benefits of alpha therapy Therapy) platform. "We are excited to have reached the successful completion of the merger with HCCC, and appreciate the ongoing support of our existing investors and new joiners to the family, as well as all of the parties involved in bringing this momentous transaction to fruition," noted Alpha Tau CEO Uzi Sofer. ", Alpha Tau CFO Raphi Levy added, "We are proud to have succeeded in executing on a large fundraising amidst a highly challenging market environment. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. For information about HCCC, please visit https://healthcarecapitalcorp.com/. Piper Sandler and Cantor Fitzgerald acted as joint placement agents on the PIPE. Founded in 2016, Alpha Tau Medical Ltd, is an Israeli oncology therapeutics company that focuses on research, development, and commercialization of the Alpha DaRT technology for the treatment of solid tumors. On July 8, 2021, Alpha Tau announced that it had entered into a definitive merger agreement (the Merger Agreement) with HCCC, a special purpose acquisition company, pursuant to which Alpha Tau would consummate the Business Combination with HCCC and become a Nasdaq-listed public company. Healthcare Capital Corp. (Exact name of registrant as specified in its charter) 301 North Market Street Suite 1414 Wilmington, DE19801 (Address of principal executive offices, including zip code) Registrant's telephone number, including area code: (561) 810-0031 Not Applicable (Former name or former address, if changed since last report) Landenburg Thalmann has initiated Healthcare Capital Corp. The investor presentation is being filed by Alpha Tau and HCC with the Securities and Exchange Commission ("SEC") and will be available on the SEC's website atwww.sec.gov. Alpha Tau believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Investors and security holders of HCCC are advised to read the definitive proxy statement filed by HCCC in connection with HCCCs solicitation of proxies for the Special Meeting because the proxy statement/prospectus contains important information about the proposed transaction and the parties to the proposed transaction. These forward-looking statements should not be relied upon as representing Alpha Tau's views as of any date subsequent to the date of this press release. The definitive proxy statement/prospectus will be mailed to stockholders of HCCC as of January 13, 2022, the record date established for voting on the proposed Business Combination. The study will be led by Gabriel Sawakuchi, Ph.D., Associate Professor of Radiation Physics, and Simona Shaitelman, M.D., Associate Professor of Radiation Oncology at MD Anderson, together with Alpha Tau's translational research and physics teams. Investors or security holders should contact Morrow Sodali LLC, HCCC's proxy solicitor, for assistance with voting of shares: Morrow Sodali LLC 333 Ludlow Street, 5th Floor, South Tower Stamford CT 06902 Tel: Toll-Free (800) 662-5200 or (203) 658-9400 Email:HCCC.Info@investor.morrowsodali.com, William Johns Chief Executive Officer and Director Healthcare Capital Corp. wjohns@healthccc.com, https://www.cstproxy.com/healthcarecapitalcorp/2022. Ellenoff Grossman & Schole LLP and FBC & Co. acted as legal advisors to HCCC. The research will focus on the mechanism of alpha radiation, with its higher relative efficiency in killing cancer cells, in comparison to traditional radiation modalities such as protons and photons, to assess any potential synergy in providing immune stimulation for enhanced destruction of breast cancer cells. ", "We are excited about Alpha Tau's unique therapy, which has generated a response observed across a wide array of solid tumors in pre-clinical studies, with minimal side effects, positioning it to potentially become a vital weapon in the battle against cancer," said Dr. David M. Milch. The combined company will continue to be led by Alpha Tau's existing management team. Share this article - Alpha Tau's proprietary Alpha DaRT . In connection with the proposed transaction with HCCC, Alpha Tau has filed a Registration Statement on Form F-4, which includes a preliminary proxy statement/prospectus of HCCC, which was declared effective on January 12, 2022. JERUSALEM and WILMINGTON, Del., March 7, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, and. When the radium decays, its short-lived daughters are released from the source and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. - Theproposedbusiness combination is expected to be completed by the end of 2021, upon which Alpha Tau is expected to be listed on Nasdaq. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. Founded in 2016, Alpha Tau is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The proxy statement/prospectus is being mailed to the Companys stockholders of record as of the close of business on the Record Date. On July 8, 2021, Alpha Tau announced that it had entered into a definitive merger agreement (the "Merger Agreement") with Healthcare Capital Corp. (Nasdaq: HCCC) ("HCCC"), a special purpose acquisition company, pursuant to which Alpha Tau would consummate a business combination transaction (the "Business Combination") with HCCC and become a . In connection with the proposed transaction with HCCC, Alpha Tau has filed a Registration Statement on Form F-4, which includes a preliminary proxy statement/prospectus of HCCC and was declared effective by the SEC on January 12, 2022. Since the alpha-emitting atoms diffuse only a short distance in tissue, Alpha DaRT mainly damages the tumor, while sparing the healthy tissue around it. These changes create opportunities for innovative business to bring solutions to market and thrive. Cantor Fitzgerald acted as a capital markets advisor to HCCC. Any such forward-looking statements represent management's estimates as of the date of this press release. Winston & Strawn LLP acted as legal advisor to the placement agents. Investors and security holders of HCCC are advised to read, the definitive proxy statement in connection with HCCC's solicitation of proxies for its special meeting of stockholders to be held to approve the proposed Business Combination because the proxy statement/prospectus contains important information about the proposed transaction and the parties to the proposed transaction. Citigroup, Piper Sandler, and Cantor Fitzgerald are acting as joint placement agents on the PIPE. Healthcare Capital Corp. All existing Alpha Tau shareholders will retain 100% of their current equity holdings and are expected to hold approximately 59% of the pro forma company immediately following the closing. The Business Combination was unanimously approved by each of Alpha Tau's and HCC's Boards of Directors, and HCC Chairman Dr. David M. Milch is expected to join the Board of Directors after closing. "Following the recent enrollment of the first patient in our flagship US feasibility study and receipt of FDA Breakthrough Device Designation, this transaction represents another significant milestone on Alpha Tau's journey to transform the treatment of solid tumors through the precision delivery of alpha radiation. BOSTON, MA and TALLAHASSEE, FL - TA Associates ("TA"), a leading global private equity firm, today announced that it has signed a definitive agreement to make a significant growth investment in Alpha II ("the Company"), a leading provider of revenue cycle management ("RCM") technology solutions to healthcare providers across the . Latham & Watkins LLP and Meitar | Law Offices acted as legal advisors to Alpha Tau. amnong@alphatau.com, Investor Relations Contacts: Any such forward-looking statements represent management's estimates as of the date of this press release. ", "This transaction ensures that we are well capitalizedto accelerate our ambitious plans across multiple fronts," said Raphi Levy, CFO of Alpha Tau. Alpha Tau believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Healthcare Capital Corp. Alpha DaRT(Diffusing Alpha-emitters Radiation Therapy) is an innovative technology that enables the highly potent and uniquely conformal alpha-irradiation of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University. This press release does not constitute (i) solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction or (ii) an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any security of HCC, Alpha Tau, or any of their respective affiliates, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Alpha Tau has developed a robust clinical trial strategy with leading global centers, including its flagship US multi-center feasibility study currently ongoing, led at Memorial Sloan Kettering Cancer Center in New York, which recently enrolled its first patient. On July 8, 2021, Alpha Tau announced that it had entered into a definitive merger agreement (the "Merger Agreement") with Healthcare Capital Corp. (NASDAQ: HCCC) ("HCCC"), a special purpose acquisition company, pursuant to which Alpha Tau would consummate a business combination transaction (the "Business Combination") with HCCC and become a . -, Healthcare Capital Corp. Reports Earnings Results for the Full Year Ended December 31, 2021, Healthcare Capital : Alpha Tau Medical and Healthcare Capital Corp. In June 2021, Alpha Tau received FDA Breakthrough Device Designation for the use of Alpha DaRT in the treatment of SCC of the skin and oral cavity without curative standard of care. The global healthcare market is undergoing significant change which is being accelerated by the global pandemic. Latham & Watkins LLP and Meitar | Law Offices acted as legal advisors to Alpha Tau. HCC was formed for the purpose of identifying emerging healthcare business that have potential to make a valuable contribution to healthcare particularly for the very large number of patients with unmet needs and to provide the capital and support they may need and to transition them to public ownership. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. HCCC will hold the Special Meeting at 10:00 AM Eastern Time on February 15, 2022, to approve, among other things, the proposed Business Combination. The firm has an $18 price target . Approximately 94.57% of the votes cast at the meeting, representing approximately 65.64% of HCCCs outstanding shares as of the record date, voted to approve the Business Combination. Or as we believe, "Do well by doing good. Additional Information and Where to Find ItFor additional information on the Business Combination, see HCCC's Current Report on Form 8-K, which was filed with the Securities and Exchange Commission ("SEC") on July 8, 2021. If you have an ad-blocker enabled you may be blocked from proceeding. , . We are delighted to work with such an extraordinary team to examine a very promising hypothesis: that Alpha DaRT may be uniquely well-suited to treat what has been a particularly deadly and intractable form of cancer.". , . NEW YORK, New York and JERUSALEM, Israel, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Healthcare Capital Corp (NASDAQ: HCCC, HCCCW, and HCCCU) ("HCCC") today announced that on January 12, 2022, the U.S. Securities and Exchange Commission ("SEC") declared effective the Registration . When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. January 19, 2022 07:40 ET HCCC will mail a definitive proxy statement/prospectus to its stockholders relating to the proposed Business Combination. Forward-Looking StatementsThis press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Medison Group, an early supporter of Alpha Tau and global pharma company that provides access to highly innovative therapies to patients in international markets, is also an investor in the PIPE. Alpha Tau's ordinary shares and warrants are expected to begin trading on Tuesday, March 8, 2022, on Nasdaq under the ticker symbols "DRTS" and "DRTSW," respectively. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. En vous inscrivant la newsletter, vous consentez la rception de contenus de notre part. When used herein, words including anticipate, being, will, plan, may, continue, and similar expressions are intended to identify forward-looking statements. You may obtain free copies of these documents as described in the preceding paragraph. "My background as a medical and radiation oncologist helped me immediately appreciate the potential of Alpha Tau's therapy in providing a solution for a potentially significant number of patients, including those with untreatable or difficult to treat tumors, whether alone or in combination with other therapies such as immunotherapies. Additional information about the proposed business combination, including a copy of the definitive agreement and investor presentation, will be provided in a Current Report on Form 8-K to be filed by HCC with the Securities and Exchange Commission and available at www.sec.gov. Healthcare Capital Corp. Reports Earnings Results for the Full Year Ended December 31, .. Healthcare Capital : Alpha Tau Medical and Healthcare Capital Corp. Type a symbol or company name. ", Alpha Tau CFO Raphi Levy added, "We are proud to have succeeded in executing on a large fundraising amidst a highly challenging market environment. Alpha Tau Medical Ltd.Amnon Gat, COO[emailprotected], Healthcare Capital Corp.William Johns, CEO[emailprotected], SOURCE Alpha Tau Medical; Healthcare Capital Corp, www.netroadshow.com/nrs/home/#!/?show=d422ce03. Alpha Tau Medical Copy and paste multiple symbols separated by spaces. This will afford us the ability to drive the company forward as we continue to execute on our ambitious plans around the world.". News and Updates Alpha Tau Medical and Healthcare Capital Corp. - Alpha Tau's proprietary Alpha DaRT is designed to deliver uniquely potent alpha radiation to destroy solid tumors with localized precision, sparing surrounding healthy tissue, thereby maintaining cancer patients' quality of life. Stockholders will also be able to obtain copies of the Registration Statement, proxy statement/prospectus, and Form 8-K, without charge at the SECs website atwww.sec.gov. ", Alpha Tau CFO Raphi Levy added, "We are proud to have succeeded in executing on a large fundraising amidst a highly challenging market environment. While Alpha Tau may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. Alpha Tau may not realize its expectations, and its beliefs may not prove correct. This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. - Alpha Tau will continue to be led by its current management team, and upon closing, it is expected that HCC Chairman Dr. David M. Milch will be appointed to the Alpha Tau Board of Directors. Alpha Tau's ordinary shares and warrants are expected to begin trading on Tuesday, March 8, 2022, on Nasdaq under the ticker symbols "DRTS" and "DRTSW," respectively. Healthcare Capital Corp. is a SPAC (Special Purpose Acquisition Company) which is listed on the Nasdaq under symbol HCCC. Alpha Tau'sproprietary Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) enables highly potent and conformal alpha-irradiation of solid tumors through the intra-tumoral insertion of radium-224 impregnated sources mainly affecting the tumor, sparing the healthy tissue around it. Alpha Tau Is Expected to Commence Trading on Nasdaq Under the Ticker "DRTS" on March 8, 2022 JERUSALEM and WILMINGTON, Del., March 7, 2022 -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, and Healthcare Capital Corp. (Nasdaq: HCCC) ("HCCC"), a special purpose acquisition company, announced today the successful closing of the . Alpha Tau may not realize its expectations, and its beliefs may not prove correct. The combined company will be named Alpha Tau Medical Ltd. and remain listed on the NASDAQ under ticker DRTS. When used herein, words including "anticipate," "being," "will," "plan," "may," "continue," and similar expressions are intended to identify forward-looking statements. Announce Stockholder Approval of the Business Combination Healthcare Capital Corp. Or as we think of it: Do Well By Doing Good. Ellenoff Grossman & Schole LLP and FBC & Co. acted as legal advisors to HCCC. Investors and security holders may obtain more detailed information regarding the names and interests in the proposed transaction of HCCC's directors and officers HCCC's and Alpha Tau's filings with the SEC, including the Registration Statement. A Current Report on Form 8-K disclosing the full voting results was filed by HCCC with the Securities and Exchange Commission on February 22, 2022. T. Alpha Tau Medical , Healthcare Capital Corp 08 Jul, 2021, 17:21 IST. Any such forward-looking statements represent management's estimates as of the date of this press release. Alpha Tau Medical and Healthcare Capital Corp. Announce Completion of.. Healthcare Capital Corp/de : Entry into a Material Definitive Agreement, Termination of a .. Healthcare Capital, Alpha Tau Medical Complete Business Combination. Alpha Tau believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation: (i) Alpha Tau's ability to receive regulatory approval for its Alpha DaRT technology or any future products or product candidates; (ii) Alpha Tau's limited operating history; (iii) Alpha Tau's incurrence of significant losses to date; (iv) Alpha Tau's need for additional funding and ability to raise capital when needed; (v) Alpha Tau's limited experience in medical device discovery and development; (vi) Alpha Tau's dependence on the success and commercialization of the Alpha DaRT technology; (vii) the failure of preliminary data from Alpha Tau's clinical studies to predict final study results; (viii) failure of Alpha Tau's early clinical studies or preclinical studies to predict future clinical studies; (ix) Alpha Tau's ability to enroll patients in its clinical trials; (x) undesirable side effects caused by Alpha Tau's Alpha DaRT technology or any future products or product candidates; (xi) Alpha Tau's exposure to patent infringement lawsuits; (xii) Alpha Tau's ability to comply with the extensive regulations applicable to it; (xiii) the ability to meet Nasdaq's listing standards following the consummation of the Business Combination; (xiv) the outcome of any legal proceedings that may be instituted against Alpha Tau or others following the consummation of the Business Combination and any definitive agreements with respect thereto(xv) the risk that the Business Combination disrupts current plans and operations of Alpha Tau as a result of the consummation of the transaction described herein; (xvi) the ability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (xvii) costs related to the Business Combination and being a public company; (xviii) changes in applicable laws or regulations; (xix) impacts from the COVID-19 pandemic; and the other important factors discussed under the caption "Risk Factors" in Alpha Tau's final proxy statement/prospectus relating to the Business Combination filed with the SEC on January 13, 2022, and other filings that Alpha Tau may make with the United States Securities and Exchange Commission.
How Many Hours Flight From Kenya To Qatar, Framesi Color Method Relief, Are Larry Mahan Boots Still Made, Ucd Accommodation 2022/23 Application, Sterilite Latch And Carry 12 Gallon, Whiteman Ride-on Power Trowel For Sale,